This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

SynCardia CardioWest TAH-t Postmarket Surveillance Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00614510
Recruitment Status : Completed
First Posted : February 13, 2008
Last Update Posted : July 30, 2015
Information provided by (Responsible Party):
SynCardia Systems. LLC

Brief Summary:
The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites that complete the staff training defined in the SynCardia Systems, Inc. Training Manual and who enroll subjects who meet the intended use defined in the product Instructions for Use.

Condition or disease Intervention/treatment
Biventricular Failure Device: CardioWest temporary Total Artificial Heart (TAH-t)

Layout table for study information
Study Type : Observational
Actual Enrollment : 196 participants
Observational Model: Cohort
Official Title: The SynCardia CardioWest Temporary Total Artificial Heart (TAH-t) Postmarket Surveillance Study
Study Start Date : August 2006
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Intervention Details:
  • Device: CardioWest temporary Total Artificial Heart (TAH-t)
    The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.

Primary Outcome Measures :
  1. Subject survival at 30-days and one-year post transplant [ Time Frame: 30-days and one-year post transplant ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who have been or will be implanted with the SynCardia Total Artificial Heart.

Inclusion Criteria:

  • The TAH-t is indicated for use as a bridge to transplant in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.

Exclusion Criteria:

  • Patients who are not cardiac transplant eligible.
  • Patients who do not have sufficient space in the chest area vacated by the natural ventricles. Generally this includes patients who have body surface areas <1.7m², or who have a distance between the sternum and the 10th anterior vertebral body measured by computed tomography imaging (CT scan) < 10 cm.
  • Patients who cannot be adequately anticoagulated on the TAH-t.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00614510

Sponsors and Collaborators
SynCardia Systems. LLC
Layout table for investigator information
Principal Investigator: Jack G Copeland, MD University Medical Center
Layout table for additonal information
Responsible Party: SynCardia Systems. LLC Identifier: NCT00614510    
Other Study ID Numbers: PR 05003
First Posted: February 13, 2008    Key Record Dates
Last Update Posted: July 30, 2015
Last Verified: March 2015